Sustainability, Impact and Practice Change
Philanthropic support is catalytic. It closes the gap between curiosity and clinical impact, empowering us to deliver on the promise of personalized, biomarker-informed lung cancer care. Join us! — Donate Today!
Our Priorities
Identify Unique Features Personalized Therapy Monitoring
Philanthropic support is catalytic. It closes the gap between curiosity and clinical impact, empowering us to deliver on the promise of personalized, biomarker-informed lung cancer care. Join us! — Donate Today!
Personalize Systemic Therapy in Lung Cancer by Integrating Biomarkers Across the Disease Continuum
Early-Stage Lung Cancer: Circulating tumor DNA (ctDNA), i.e., DNA shed from tumor cells into the bloodstream has emerged as a noninvasive diagnostic for detection of minimal residual disease (MRD) and identifying patients at higher risk of progression following curative-intent treatment.
Early-stage NSCLC patients with positive ctDNA before and after neoadjuvant therapy experience worse overall survival and progression-free survival compared to those with negative ctDNA.
Persistent ctDNA positivity during neoadjuvant therapy may indicate therapeutic resistance and the need for escalated therapy.
As a biomarker, ctDNA offers a valuable tool for risk stratification, enabling personalized treatment strategies.
Metastatic Lung Cancer: Our efforts will focus on personalizing treatment using biomarkers throughout all lines of therapy. ctDNA will be used to detect early molecular progression, identify mechanisms of resistance and monitor response to targeted and immunotherapies.
The goal is to transition from empirical management to biologically guided therapy modification to ensure effective treatments at each disease milestone.
With sustained research funding, we can personalize treatment for every patient, ensuring the right therapy is delivered at the right moment, with the best possible chance for cure or control.
Philanthropic support is catalytic. It closes the gap between curiosity and clinical impact, empowering us to deliver on the promise of personalized, biomarker-informed lung cancer care. Join us! — Donate Today!
ctDNA MRD Testing and Monitoring. Circulating tumor DNA (ctDNA), i.e., DNA shed from tumor cells into the bloodstream has emerged as a noninvasive diagnostic for detection of minimal residual disease (MRD) and identifying patients at higher risk of progression following curative-intent treatment.
We believe that ctDNA MRD testing and monitoring will soon become mainstream. In general, MRD tests are either tumor-informed or tumor-agnostic, depending on whether the patient’s tissue biopsy sequencing is used to design the assay.
ctDNA MRD remains exploratory for patients with early-stage NSCLC, which exemplifies the need to specifically test clinical utility of ctDNA MRD to predict outcomes for patients with early-stage NSCLC.
With sustained research funding, we can evaluate the clinical utility of ctDNA MRD assays in
Philanthropic support is catalytic. It closes the gap between curiosity and clinical impact, empowering us to deliver on the promise of personalized, biomarker-informed lung cancer care. Join us! — Donate Today!